{
    "clinical_study": {
        "@rank": "60207", 
        "arm_group": [
            {
                "arm_group_label": "Influenza vaccination Timing #1", 
                "arm_group_type": "Other", 
                "description": "Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4)."
            }, 
            {
                "arm_group_label": "Influenza vaccination Timing #2", 
                "arm_group_type": "Other", 
                "description": "Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will compare the immunogenicity of influenza vaccine in adults and\n      children with inflammatory bowel disease by timing of vaccine in relation to maintenance\n      infliximab dosing. The primary objective is to compare the proportion of IBD patients on\n      maintenance infliximab who mount serologic protection to each component of the influenza\n      vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and\n      patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Serologic\n      protection will be defined by a hemagglutination-inhibition titer \u2265 1:40. The secondary\n      objective is to compare the proportion of IBD patients who mount an immunogenic response (\u2265\n      4-fold increase from pre to post-vaccination titer) to each component of the influenza\n      vaccination between patients vaccinated on day of infliximab infusion and those vaccinated\n      at the mid-point."
        }, 
        "brief_title": "Infliximab IBD Influenza Vaccine Study", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Inflammatory Bowel Disease", 
        "condition_browse": {
            "mesh_term": [
                "Inflammatory Bowel Diseases", 
                "Influenza, Human", 
                "Intestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of IBD established by accepted criteria\n\n          -  On maintenance infliximab administered every 6 to 8 weeks (already received at least\n             6 weeks of infliximab)\n\n          -  Between ages 9 and 60 years\n\n        Exclusion Criteria:\n\n          1. Pregnancy\n\n          2. Hypersensitivity reaction to previous dose of influenza vaccine\n\n          3. Known hypersensitivity to eggs or chicken or other components of influenza vaccine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "9 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666535", 
            "org_study_id": "REMICADEIBD4010"
        }, 
        "intervention": {
            "arm_group_label": [
                "Influenza vaccination Timing #1", 
                "Influenza vaccination Timing #2"
            ], 
            "intervention_name": "Influenza vaccination", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza vaccine", 
            "Immune response", 
            "Remicade (infliximab)", 
            "Inflammatory bowel disease"
        ], 
        "lastchanged_date": "August 10, 2012", 
        "location": {
            "contact": {
                "email": "jennifer.debruyn@albertahealthservices.ca", 
                "last_name": "Jennifer deBruyn"
            }, 
            "facility": {
                "address": {
                    "city": "Calgary", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T3B 6A8"
                }, 
                "name": "University of Calgary"
            }, 
            "investigator": [
                {
                    "last_name": "Jennifer deBruyn, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Remo Panaccione,, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Iwona Wrobel, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cynthia Seow, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Influenza Vaccination Timing on Immune Response in Patients With Inflammatory Bowel Disease on Infliximab Therapy: A Randomized Equivalence Trial", 
        "other_outcome": [
            {
                "description": "To evaluate the number of participants with early serious adverse reactions (\u2264 3 days post-vaccination)", 
                "measure": "Number of participants with serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 days post vaccination"
            }, 
            {
                "description": "To evaluate the change in disease activity score from baseline using the validated instruments of the Pediatric Ulcerative Colitis Activity Index for participants with Ulcerative Coltiis and the Harvey Bradshaw Index for participants with Crohn's Disease", 
                "measure": "Change in disease activity from baseline", 
                "safety_issue": "No", 
                "time_frame": "Four week post-vaccination"
            }
        ], 
        "overall_contact": {
            "email": "jennifer.debruyn@albertahealthservices.ca", 
            "last_name": "Jennifer deBruyn"
        }, 
        "overall_official": {
            "affiliation": "University of Calgary", 
            "last_name": "Jennifer deBruyn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the proportion of IBD patients on maintenance infliximab who mount serologic protection to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Serologic protection will be defined by a hemagglutination-inhibition titer \u2265 1:40.", 
            "measure": "Serologic protection", 
            "safety_issue": "No", 
            "time_frame": "28 days \u00b1 3 days after influenza vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666535"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Calgary", 
            "investigator_full_name": "Jennifer deBruyn", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To compare the proportion of IBD patients on maintenance infliximab who mount an immunogenic response to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion (Day 0 to 4) and patients vaccinated at the mid-point between infliximab infusions (Day 21 to 28).  Immunogenicity will be defined as a fourfold or greater differences in titer between pre and post-vaccination sera.", 
            "measure": "Immunogenic response", 
            "safety_issue": "No", 
            "time_frame": "28 days \u00b1 3 days after influenza vaccination"
        }, 
        "source": "University of Calgary", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Calgary", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}